Advanced search    

Search: authors:"Nadia Harbeck"

25 papers found.
Use AND, OR, NOT, +word, -word, "long phrase", (parentheses) to fine-tune your search.

Correction to: Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial

, Steven Shak, Rachel Wuerstlein, Hans H. Kreipe, Nadia Harbeck, was originally published electronically on the publisher’s internet portal (currently SpringerLink) on June 29, 2017 without open access.With

Impact of Etoposide on BRCA1 Expression in Various Breast Cancer Cell Lines

Hofmann, Nadia Harbeck, Udo Jeschke, and Sophie Sixou declare that they have no conflict of interest. Funding Sophie Sixou’s salary was supported by the University Paul Sabatier in Toulouse (France

Role of postoperative radiotherapy in reducing ipsilateral recurrence in DCIS: an observational study of 1048 cases

The objective of the present study was to evaluate the effectiveness of postoperative radiotherapy after breast conserving surgery (BCS) in DCIS in a large patient population treated in clinical practice. Data were provided by the population-based Munich Cancer Registry. Between 1998 and 2014, 1048 female patients with diagnosis of DCIS and treated at two Breast Care Centres were...

15. Internationale St.-Gallen-Konsensus-Konferenz: Behandlung des frühen Mammakarzinoms

]) sowie der St. Gallen Panel Expert: Univ.-Prof. Dr. med. Jens Huober, Univ.-Prof. Dr. med. Nadia Harbeck. S3-Leitlinie [11], deren Aktualisierung vor der Fertigstellung steht, kommentiert. Die 15. St

uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies

Urokinase plasminogen activator (uPA) is an extracellular matrix-degrading protease involved in cancer invasion and metastasis, interacting with plasminogen activator inhibitor-1 (PAI-1), which was originally identified as a blood-derived endogenous fast-acting inhibitor of uPA. At concentrations found in tumor tissue, however, both PAI-1 and uPA promote tumor progression and...

Erratum to: ‘Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

O'Shaughnessy 8 Robert M. Beck 4 Amy Ko 4 Markus F. Renschler 4 Debora Barton 4 Nadia Harbeck 7 0 Weston Park Hospital, Sheffield Cancer Research Center , Sheffield, England 1 University of Pittsburgh Medical

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs

PTK7 as a potential prognostic and predictive marker of response to adjuvant chemotherapy in breast cancer patients, and resistance to anthracycline drugs Beyhan Ataseven,1,2 Angela Gunesch,2 Wolfgang Eiermann,3 Ronald E Kates,4 Bernhard Högel,5 Pjotr Knyazev,6 Axel Ullrich,6 Nadia Harbeck4 1Department of Gynecology and Gynecologic Oncology, Kliniken Essen-Mitte, Essen, Germany...

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial

. Nabholtz 3 Joyce O'Shaughnessy 8 Robert M. Beck 4 Amy Ko 4 Markus F. Renschler 4 Debora Barton 4 Nadia Harbeck 7 0 Weston Park Hospital, Sheffield Cancer Research Center , Sheffield, England 1 University of

WSG ADAPT – adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator initiated phase II/III trial

Background Adjuvant treatment decision-making based on conventional clinical/pathological and prognostic single molecular markers or genomic signatures is a therapeutic area in which over-/under-treatment are still key clinical problems even though substantial and continuous improvement of outcome has been achieved over the past decades. Response to therapy is currently not...

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study

Purpose The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer (MBC). Methods This randomized, phase III, open-label, multicenter trial enrolled first-line MBC patients who were ineligible for endocrine or trastuzumab therapy. Cumulative adjuvant...

Elucidating Pretreatment Cognitive Impairment in Breast Cancer Patients: The Impact of Cancer-Related Post-Traumatic Stress

Herschbach , Nadia Harbeck Background: Pretreatment cognitive impairment in cancer patients is well established but unexplained. Similar cognitive compromise has been observed in post-traumatic stress

The patient experience

The impact of improved treatments for the management of hormone-sensitive breast cancer extends beyond clinical responses. Thanks to appropriate literature and access to the internet, patient awareness of treatment options has grown and patients are now, in many cases, able to engage their oncologists in informed conversations regarding treatment and what to expect in terms of...

Recent advances in technologies for the detection of occult metastatic cells in bone marrow of breast cancer patients

Approximately half of breast cancer patients with stage I–III disease will suffer metastatic disease despite resection with tumour-free margins. In 30–40% of these patients, individual carcinoma cells can already be detected at the time of primary therapy in cytological bone marrow preparations using immunocytochemistry. Numerous prospective clinical studies have shown that the...

Feasibility of Measuring the Prognostic Factors uPA and PAI-1 in Core Needle Biopsy Breast Cancer Specimens

tumor heterogeneity, two or three biopsy specimens should be assessed. CHRISTOPH THOMSSEN NADIA HARBECK JUERGEN DITTMER SHANTI R. ABRAHA-SPAETH NANCY PAPENDICK ANGELO PARADISO BJOERN LISBOA FRITZ

Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching

Several large, well-controlled clinical trials have now established that the aromatase inhibitors (AIs), including letrozole, anastrozole, and exemestane, are more effective than tamoxifen when used as adjuvant endocrine therapy in postmenopausal women with breast cancer. Yet, it is an open question as to how these drugs should be best integrated into the adjuvant treatment...

Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: Phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6 × FEC versus 3 × FEC/3 × Docetaxel

Fritz Jaenicke 10 Christoph Thomssen 3 Nadia Harbeck 11 0 Centre Henri Becquerel, OB-GYN , Rouen , France 1 Klinik fur Gynakologie, Johannes Gutenberg-Universitat , Mainz , Germany 2 Laboratoire de

CDO1 Promoter Methylation is a Biomarker for Outcome Prediction of Anthracycline Treated, Estrogen Receptor-Positive, Lymph Node-Positive Breast Cancer Patients

Background Various biomarkers for prediction of distant metastasis in lymph-node negative breast cancer have been described; however, predictive biomarkers for patients with lymph-node positive (LNP) disease in the context of distinct systemic therapies are still very much needed. DNA methylation is aberrant in breast cancer and is likely to play a major role in disease...